Table 1.

Results from antiretroviral drug testing and HIV drug resistance testing for participants who had HIV drug resistance at study entry (screening) or at the end of study follow-up (12 months).

Start of study						End of study
Case	Viral Load	NRTIs detected	NNRTIs detected	Major NRTI mutations	Major NNRTI mutations	Viral Load	NRTIs detected	NNRTIs detected	PIs detected	Major NRTI mutations	Major NNRTI mutations
1	18,900	3TC	NVP	M184V	K103N	<400	3TC, TDF	-	ATV/r	N/A	N/A
2	480	3TC, TDF	EFV	-	K103N	<400	3TC, TDF	EFV	-	N/A	N/A
3	34,100	-	-	-	K103N	<400	3TC, TDF	EFV	-	N/A	N/A
4	1,180	-	-	-	K103N	<400	FTC, TDF	EFV	-	N/A	N/A
5	8,440	-	-	-	K103N	<400	FTC, TDF	EFV	-	N/A	N/A
6	43,200	-	-	-	Y188C	34,720	-	-	-	-	-
7	195,990	-	-	-	K103N, G190A	4,770	-	-	-	-	K103N
8	17,520	-	EFV	M184I	K103N, V106M	1,280	FTC, TDF	EFV	-	L74V, M184V	K103N, V106M
9	430	-	EFV	-	-	4,510	FTC, TDF	EFV	-	K65R	K103N, Y188C
10	48,100	-	-	-	-	21,910	3TC, TDF	EFV	-	K65R	K103N, V106M

The table shows results of antiretroviral drug testing and HIV drug resistance testing. Testing was performed at the start of the study (screening visit) and at the end of the study (12-month visit). Results are shown only for participants who had HIV drug resistance mutations detected at one or both visits. HIV viral load values are shown as copies/mL. HIV drug resistance testing was not performed at 12 months for five virally suppressed participants (N/A).

Abbreviations: NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; NVP, nevirapine; EFV, efavirenz; ATZ, atazanavir; and r, ritonavir.